NEWS
FSD Pharma Receives Institutional Review Board Approval to Study the Safety and Efficacy of Unbuzzd(TM) in Acute Alcohol Intoxication
FSD Pharma has received Institutional Review Board (IRB) approval for its METAL-2 trial in the USA to study the safety and efficacy of Unbuzzd(TM) in acute alcohol intoxication. This approval allows the company to begin recruiting participants and planning the clinical study. Dr. Andrzej Chruscinski, Vice-President of Clinical and Scientific Affairs, emphasized the significance of this milestone in advancing research on acute alcohol intoxication.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment